title: Cost-effectiveness of prophylaxis in total hip replacement.
abstract: A theoretical analysis was performed regarding the cost-effectiveness in terms of lives saved (reduction of fatal pulmonary embolism [PE]) and in terms of money (dollars spent for prevention and treatment) of seven strategies in the management of venous thromboembolic disease in patients over 39 years of age undergoing elective total hip replacement (THR). Strikingly, this theoretical analysis suggests that low-dose warfarin combined with clinical surveillance of deep vein thrombosis would reduce the incidence of fatal PE from 20 per 1,000 patients to 4 per 1,000 patients and simultaneously reduce the charges for venous thromboembolic disease from $550,000 to about $400,000 per 1,000 patients. Based on this analysis, we strongly recommend this measure on a routine basis. Adding venography or duplex sonography routinely to this prophylactic regimen would, in this theoretical analysis, reduce the incidence of fatal PE from 4 per 1,000 patients to 0.15 per 1,000, but adds charges of $200,000 per extra life saved in the case of routine venography and $50,000 in the case of routine sonography. Low-dose warfarin prophylaxis combined with routine sonography does not generate more charges than no prophylaxis with no screening while drastically reducing the incidence of fatal PE from 20 to 0.3 per 1,000 patients. Where duplex sonography is not easily available, a 12-week postoperative course of low-dose warfarin for every patient with no routine screening will be efficacious in reducing fatal PE and as cost-effective.
authors.affiliation: Division of Orthopedics, University of Montreal Medical School, Quebec, Canada.
authors.forename: G D
authors.initials: GD
authors.lastname: Paiement
authors.forename: S J
authors.initials: SJ
authors.lastname: Wessinger
authors.forename: W H
authors.initials: WH
authors.lastname: Harris
mesh_terms: D000328:Adult; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D006470:Hemorrhage / Q000139:chemically induced / Q000191:economics; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006622:Hip Prosthesis; D006801:Humans; D010690:Phlebography / Q000191:economics; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control*; D011322:Primary Prevention / Q000191:economics; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging / Q000191:economics / Q000517:prevention & control; D013923:Thromboembolism / Q000000981:diagnostic imaging / Q000191:economics / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000000981:diagnostic imaging / Q000191:economics / Q000517:prevention & control; D014463:Ultrasonography; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014859:Warfarin; D006493:Heparin